Description
Anti-LGR7 Antibody, Non-Fucosylated (BioBet-1254ZP) is a human monoclonal IgG antibody against LGR7. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Adenocarcinoma; Ovarian Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced LGR7 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
RXFP1
Full Name
relaxin/insulin-like family peptide receptor 1
Background
This gene encodes a member of the leucine-rich repeat-containing subgroup of the G protein-coupled 7-transmembrane receptor superfamily. The encoded protein plays a critical role in sperm motility, pregnancy and parturition as a receptor for the protein hormone relaxin. Decreased expression of this gene may play a role in endometriosis. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Alternative Names
RXFP1; relaxin/insulin-like family peptide receptor 1; LGR7; RXFPR1; relaxin receptor 1; leucine-rich repeat-containing G protein-coupled receptor 7
Gene ID
59350
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with RXFP1 include Placenta Accreta and Endometriosis.
Related Pathways
Its related pathways are Signaling by GPCR and GPCRs, Other.
Function
Receptor for relaxin. The activity of this receptor is mediated by G protein, leading to stimulation of adenylate cyclase and an increase in cAMP. The binding of ligand may also activate the tyrosine kinase pathway and inhibit the activity of phosphodiesterase that degrades cAMP.
Post-translational modifications
1.Glycosylation at Asn36, Asn127, Asn325, Asn264, Asn272, and Asn368 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
22DA23
Description
The anti-LGR7 antibody have antibody-dependent cell-mediated cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity against LGR7-expressing cells. The anti-LGR7 antibody are useful for diagnosis, prevention, and treatment of primary and metastatic ovarian clear cell adenocarcinoma.
Antibody Indication
Adenocarcinoma; Ovarian Cancer
Adenocarcinoma; Ovarian Cancer
